Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients With Recurrent or Refractory Active Chronic Graft Versus Host Disease Who Have Received at Least 2 Lines of Systemic Therapy

Next Previous
Trial Profile

AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients With Recurrent or Refractory Active Chronic Graft Versus Host Disease Who Have Received at Least 2 Lines of Systemic Therapy

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axatilimab (Primary)
  • Indications Graft-versus-host disease
  • Focus Registrational; Therapeutic Use
  • Acronyms AGAVE-201
  • Sponsors Syndax Pharmaceuticals

Most Recent Events

  • 03 Nov 2025 According to a Syndax Pharmaceuticals media release, data form the trial were accepted for presentation at the 67th American Society of Hematology (ASH) Annual Meeting being held in Orlando, Florida, December 6-9, 2025.
  • 03 Nov 2025 According to an Incyte corporation media release, data from the study will be presented in both oral and poster sessions at the 2025 American Society of Hematology (ASH) Annual Meeting, to be held December 6 to 9, 2025, in Orlando.
  • 14 May 2025 According to a Syndax Pharmaceuticals media release, data from this study will be presented at the 30th European Hematology Association (EHA) Annual Congress Meeting being held June 12-15, 2025, in Milan, Italy.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top